OASMIA PHARMACEUTICAL AB Inactive Instrument
Oasmia Pharmaceutical AB Stock NORDIC GROWTH MARKET
Equities
OASM
SE0000722365
Pharmaceuticals
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.04M 283K 386K | Sales 2023 | 6.61M 616K 839K | Capitalization | 219M 20.44M 27.81M |
|---|---|---|---|---|---|
| Net income 2022 | -357M -33.28M -45.28M | Net income 2023 | -129M -12.03M -16.36M | EV / Sales 2022 | 32.6 x |
| Net cash position 2022 | 134M 12.52M 17.04M | Net cash position 2023 | 77.04M 7.18M 9.77M | EV / Sales 2023 | 21.5 x |
| P/E ratio 2022 |
-0.6
x | P/E ratio 2023 |
-1.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Oasmia Pharmaceutical AB
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +32.27% | 588B | |
| -3.28% | 364B | |
| +19.24% | 326B | |
| +4.88% | 285B | |
| +15.51% | 239B | |
| +10.35% | 210B | |
| -7.16% | 200B | |
| +8.67% | 167B | |
| -0.49% | 161B |
